explore -WSS

explore

author：hotspot 2025-09-30 22:04:53 - browse：18586

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

entertainment

WSS

Congress likely to miss an opportunity to fix drug shortages issue

J&J expands global access to TB drug amid advocacy campaign

Medicare coverage of Wegovy, once blocked, now looks possible

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Can CDC director Mandy Cohen drive consensus in Washington?

Readout Newsletter: CAR

Wikipedia

explore

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Grail faces three suits alleging harassment, retaliation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

EPA limits use of carcinogenic gas for sterilizing medical devices

In Memoriam: Notable people who died in 2023

How to save health care price transparency rules

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UCLA team creates talking throat patch for voice disorders

Medical leaders decry Supreme Court decision on affirmative action

The new HIV moral panic

focus

As AI in medicine takes off, can 'human in the loop' prevent harm?

Steward Health Care Massachusetts hospitals face fiscal disaster

Medicare coverage of Wegovy, once blocked, now looks possible

Woman gored by Bison at Yellowstone

EPA limits use of carcinogenic gas for sterilizing medical devices

FDA advisers back CAR

entertainment

leisure time

knowledge

explore